MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy

By A. Kasinski, Frank J. Slack. Nature Reviews. Cancer, 2011

951 citations recorded by the source corpus.

In normal cells multiple microRNAs (miRNAs) converge to maintain a proper balance of various processes, including proliferation, differentiation and cell death. miRNA dysregulation can have profound cellular consequences, especially because individual miRNAs can bind to and regulate multiple mRNAs. In cancer, the loss of tumour-suppressive miRNAs enhances the expression of target oncogenes, whereas increased expression of oncogenic miRNAs (known as oncomirs) can repress target tumour suppressor genes. This realization has resulted in a quest to understand the pathways that are regulated by these miRNAs using in vivo model systems, and to comprehend the feasibility of targeting oncogenic miRNAs and restoring tumour-suppressive miRNAs for cancer therapy. Here we discuss progress in using mouse models to understand the roles of miRNAs in cancer and the potential for manipulating miRNAs for cancer therapy as these molecules make their way towards clinical trials.

Subfields: Cancer Research, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/e0474da1f4902f921fd894216f1c440e0d23b51d

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. A. Bader
2. M. Jansson
3. A. Lund

In Molecular Biology

1. A. Bader
2. M. Jansson
3. A. Lund

Citations in the corpus

• Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors (2016, background): “Numerous studies using cultured cells and animal models have identified miRNAs that can function as conventional tumor suppressors or oncogenes, and have demonstrated that the introduction or repression of a single miRNA can effectively contribute to tumorigenesis, tumor progression, or regression [”
• Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours (2020, neutral): “Hyponatremia – 14 (17) 2 (2) – 7 (23) – – 4 (10) 2 (5) – 2 (33) –”
• MicroRNA and cancer (2012, background): “In addition to directly repairing DNA breaks or adducts, cells respond to DNA damage by halting cell-cycle progression or by undergoing apoptosis (Kastan and Bartek, 2004).”